Christopher Sweeney
Medical Oncology · Boston, MANPI 1659337038
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $43,585 of the $56,982 with a category attached, or 76.5%. 14 manufacturers reported payments, led by Bayer at 25.6% of the total. Reporting peaked in 2022 at $17,993 and has fallen 99.4% since, to $105 in 2023.
Across 46 payments — averaging $1238.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$15K
- Eli Lilly$13K
- Pfizer$6K
- Advanced Accelerator Applications$4K
- Bristol Myers Squibb$4K
- E.r. Squibb & Sons, L.L.C.$3K
- plus $13K from 8 others
Across 41 payments — averaging $15,727 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$225K
- Genentech, Inc.$156K
- Exelixis Inc.$147K
- Bayer$70K
- Sanofi$20K
- F. Hoffmann-la Roche AG$14K
- plus $12K from 1 others
What the payments were for
- Consulting fees$43,58576%
- Speaking & faculty fees$12,15221%
- Travel & lodging$4991%
- Food & beverage$7461%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 5 | $14,566 |
| Eli Lilly | 17 | $12,844 |
| Pfizer | 4 | $5,625 |
| Advanced Accelerator Applications | 2 | $4,125 |
| Bristol Myers Squibb | 2 | $3,710 |
| E.r. Squibb & Sons, L.L.C. | 3 | $3,360 |
| Sanofi | 3 | $3,163 |
| F. Hoffmann-la Roche AG | 2 | $3,132 |
| Genentech, Inc. | 2 | $2,672 |
| AstraZeneca | 1 | $1,370 |
| Daiichi Sankyo Inc. | 1 | $938 |
| Roche Products Limited | 2 | $695 |
| GSK | 1 | $650 |
| Astrazeneca UK Limited | 1 | $131 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Nubeqa$12,613
- CC-90011$3,710
- Perjeta$3,132
- XTANDI$3,105
- JEVTANA$2,876
- Non-Covered Product$2,640
- TALZENNA$2,625
- Lutathera$2,000
- Non-Covered$1,680
- OPDIVO$1,280
- NO PRODUCT DISCUSSED$287
- VERZENIO$124
How this compares
$56,982 in reported general payments places this provider in the 75th percentile of 308 medical oncology providers in Massachusetts.
Other medical oncology in Boston
- George DemetriBoston$1.6M
- Keith FlahertyBoston$932K
- Alicia MorgansBoston$690K
- Pasi Antero JanneBoston$458K
- Robert HaddadBoston$451K
- Irene GhobrialBoston$431K
- Joaquin Bellmunt MolinsBoston$415K
- Jeremy AbramsonBoston$334K
- Justin GainorBoston$324K
- Narjust FlorezBoston$324K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.